JP2024112859A5 - - Google Patents

Download PDF

Info

Publication number
JP2024112859A5
JP2024112859A5 JP2024077300A JP2024077300A JP2024112859A5 JP 2024112859 A5 JP2024112859 A5 JP 2024112859A5 JP 2024077300 A JP2024077300 A JP 2024077300A JP 2024077300 A JP2024077300 A JP 2024077300A JP 2024112859 A5 JP2024112859 A5 JP 2024112859A5
Authority
JP
Japan
Prior art keywords
composition
months
seq
determined
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024077300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024112859A (ja
JP7875901B2 (ja
Filing date
Publication date
Priority claimed from JP2021503770A external-priority patent/JP7541505B2/ja
Application filed filed Critical
Publication of JP2024112859A publication Critical patent/JP2024112859A/ja
Publication of JP2024112859A5 publication Critical patent/JP2024112859A5/ja
Priority to JP2026031310A priority Critical patent/JP2026097906A/ja
Application granted granted Critical
Publication of JP7875901B2 publication Critical patent/JP7875901B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024077300A 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法 Active JP7875901B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026031310A JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
JP2021503770A JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021503770A Division JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026031310A Division JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Publications (3)

Publication Number Publication Date
JP2024112859A JP2024112859A (ja) 2024-08-21
JP2024112859A5 true JP2024112859A5 (cg-RX-API-DMAC7.html) 2025-03-06
JP7875901B2 JP7875901B2 (ja) 2026-06-18

Family

ID=67551415

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021503770A Active JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法
JP2024077300A Active JP7875901B2 (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法
JP2026031310A Pending JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021503770A Active JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026031310A Pending JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Country Status (11)

Country Link
US (1) US20210324056A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826674A2 (cg-RX-API-DMAC7.html)
JP (3) JP7541505B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210039402A (cg-RX-API-DMAC7.html)
CN (2) CN118924896A (cg-RX-API-DMAC7.html)
AU (2) AU2019309938B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107370A1 (cg-RX-API-DMAC7.html)
IL (3) IL310132B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000778A (cg-RX-API-DMAC7.html)
PH (1) PH12021500006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
PT4121007T (pt) * 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Similar Documents

Publication Publication Date Title
JP2021532126A5 (cg-RX-API-DMAC7.html)
Yang et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder
JP2022033868A5 (cg-RX-API-DMAC7.html)
JP2020002171A5 (cg-RX-API-DMAC7.html)
AU2019309938B2 (en) Methods of treatment and prevention of Alzheimer's disease
MD3478712T2 (ro) Anticorpi peptidici beta amiloizi anti-N3pGlu și utilizări ale acestora
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP2023548858A5 (cg-RX-API-DMAC7.html)
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
JPH08511005A (ja) 神経疾患の治療におけるアルカリ性または酸性ホスファターゼインヒビター
JP2022525164A5 (cg-RX-API-DMAC7.html)
JP2023520516A5 (cg-RX-API-DMAC7.html)
JP2021502349A5 (cg-RX-API-DMAC7.html)
JP2023527542A5 (cg-RX-API-DMAC7.html)
JP2020502261A5 (cg-RX-API-DMAC7.html)
JP2020535149A5 (cg-RX-API-DMAC7.html)
US20250377367A1 (en) Methods of treatment using p-tau181 level
CN110891586A (zh) 用于疗法中的s-亚硝基谷胱甘肽(gsno)和gsno还原酶抑制剂
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
JP2021523138A5 (cg-RX-API-DMAC7.html)
JP2024532438A5 (cg-RX-API-DMAC7.html)
JP2024540226A5 (cg-RX-API-DMAC7.html)
JP2024540294A5 (cg-RX-API-DMAC7.html)
JP2023510854A5 (cg-RX-API-DMAC7.html)
JP2024547001A5 (cg-RX-API-DMAC7.html)